LBA32 A Randomized, Phase II, Dose Optimization of Gotistobart, a Ph-Sensitive Anti-Ctla-4, in Combination with Standard Dose Pembrolizumab in Platinum-Resistant Recurrent Ovarian Cancer: Safety, Efficacy and Dose Optimization (PRESERVE-004/GOG-3081)

J.N. Barlin, P.C. Lim, J. Thomes Pepin, E.E. Hopp,N.G. Cloven, C. Lee, H.D. Eshed,D. Black, H.M. Cottrill, L. Hand, D.M. O'Malley,L.T. Chuang,L. Willmott,M. Chisamore, S. Shpyro, J. Durbin, P. Zheng, Y. Liu, B.J. Monk

Annals of Oncology（2024）

引用 0|浏览4